MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...
GlobalData on MSN17h
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...
Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...
in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his colleagues ...
To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...
HealthDay on MSN9d
Why treatments can fail patients with 'wet' macular degenerationCurrent treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think ...
An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback